FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
The landscape of rare coagulation factor deficiency management in Italy: a national hemophilia center survey
1217PDF: 177HTML: 100Appendix: 97 -
Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers
755PDF: 91HTML: 86Supplementary: 48Appendix: 61 -
Anticoagulation in obese patients: challenges and strategies
1948PDF: 308HTML: 272XML: 154 -
The key to fibrinolysis and thrombolysis
1608PDF: 344HTML: 212 -
OC09 | BLEEDING RISK ASSOCIATED WITH FACTOR XI MONOCLONAL ANTIBODIES IN COMBINATION WITH ASPIRIN IN HEALTHY VOLUNTEERS AND ORTHOPEDIC SURGERY PATIENTS: ANALYSIS FROM RECENT PHASE 1 AND PHASE 2 STUDIES A.P. Kithcart1, M.E. Burczynski1, P. Banerjee1, M. Onisko1, Y. Wang1, K. Mohammadi1, D. Li1, S. Li1, J. Ackroyd2, B.A. Olenchock1, D.E. Gutstein1, J. I. Weitz3 | 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Clinical Research, Fortrea Clinical Research Unit Ltd, Leeds, UK; 3McMaster University, Hamilton, ON, Canada
268PDF: 79 -
PO49 | Use of emicizumab in two patients with acquired hemophilia A: a new therapeutic approach S. Sorella, J. Micozzi, E. Baldacci, M. Biglietto, R. Mormile, A. Chistolini, R. Ciciani, L. Torrieri, N. Zhdanovskaya, M. Lorenzon, A. Delli Paoli, S. Ligia, C. Santoro | Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Roma, Italy
582PDF: 0 -
PO67 | Pancreatic cancer in a 71-year-old severe hemophilia A patient with inhibitors and sustained zero bleeding during emicizumab prophylaxis M. Biglietto, A.L. Faccini, S. Sorella, E. Crisanti, M. Antonacci, A. Taglietti, M. Gherardini, A. Tirnetta, S. Ligia, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy
581PDF: 0 -
PO40 | Management of paediatric patients affected by mild factor VII deficiency undergoing surgery B. Borsellino1,2, B. Pollio1, I. Ricca1, R. Albiani1, T. Martini1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Turin; 2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Roma Tor Vergata, Roma, Italy
516PDF: 0 -
PO39 | Bleeding events in Von Willebrand disease type 1 yearly treatable with desmopressin A. Gringeri1,2, P.M. Mannucci3, M. Gringeri4, G. Castaman5, F. Peyvandi3,6 | 1Fondazione Charta, Milan; 2Centro di Sanità Solidale, Lucca; 3Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan; 4Department of Medical Biotechnologies and Translational Medicine, Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan; 5Centre for Bleeding Disorders and Coagulation, Careggi University Hospital, Firenze; 6Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Italy
562PDF: 0 -
PO56 | Safety of anticoagulant treatment in patients with splanchnic vein thrombosis and history of portal hypertension-related bleeding R. Talerico1, S. Pellegrino1, A. Plessier2, F.R. Ponziani3, A. Porfidia1, F. Landi1, A. Gasbarrini3, R. Pola1, F. Santopaolo3 | 1Department of Geriatric, Orthopedic, and Rheumatologic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; 2Université de Paris, AP-HP, C, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVE. Centre de recherche sur l’inflammation, Inserm, Paris, France; 3Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy
547PDF: 0 -
PO55 | Evaluation of safety and efficacy of emicizumab prophylaxis in pediatric patients with hemophilia A – a single centre experience M.L. Tramontano, M. Coppola, S. Coppola, M. Schiavulli | UOSD Centro Regionale Pediatrico Malattie della Coagulazione, Santobono Pausilipon Children Hospital, AORN, Napoli, Italy
516PDF: 0 -
PO24 | Emicizumab prophylaxis and bleeding outcomes: a single center clinical experience A. Taglietti1, S. Ligia1, F. Paoletti1, R. Mormile1, E. Baldacci2, A. Chistolini1, C. Santoro1,2 | 1Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma; 2Hematology, Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Italy
565PDF: 0 -
CO35 | Bleeding phenotype characterization in patients with congenital bleeding disorders: a multigenic approach using next generation sequencing to identify coagulation-modulating variants C. Simion, L. Gianesello, C. Bulato, A. Benetti, E. Campello, A. Giannella, G. Ceolotto, E. Zanon, L. Spiezia, P. Simioni | Department of Medicine – DIMED, University of Padua, Italy
486PDF: 0 -
PO41 | Comparison of the haemorrhagic phenotype between female and male patients affected by autosomal inherited bleeding disorders in a single-centre cohort B. Borsellino1,3, C. Zuccotti2, L. Guarnera3,4, C. Biasoli5, P. Pedrazzi5, T. Martini1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Turin, Italy; 2Department of Clinical Pathology, Bufalini Hospital, Cesena, Italy; 3Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Roma Tor Vergata, Roma, Italy; 4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA; 5Haemophilia and Transfusion Centre, Bufalini Hospital, Cesena, Italy
552PDF: 0 -
CO29 | Emergency room physicians and oral anticoagulants related bleeding D. Barcellona1,2, G. Melis1, A. Bussu1, M. Orrù1, Ml. Caddeo1, E. Antonucci2, A. Mameli1, F. Marongiu1,2 | 1SSD Emostasi e Trombosi, AOU Cagliari; 2Fondazione Arianna, Bologna, Italy
592PDF: 0 -
PO02 | Pregnancy and delivery in women with hemophilia and carriers are still challenging: a ten years analysis from The Italian Association of Hemophilia Centers (AICE) M. Napolitano1, M. Mattana2, C. Cammarata1, M. Leotta3, S. Linari4, M.E. Mancuso5, G. F. Rivolta6, C. Santoro7, L. Valdrè8, R.C. Santoro3, S. Siragusa1 | 1Department of Health Promotion, Mother and Child Care, Internal Medicine and Med, Palermo; University of Palermo, Italy; 2Department of Precision Medicine in Medical, Surgical and Critical Care “Me. Pre. Cc”, University of Palermo; 3Hemostasis and Thrombosis Unit, Azienda Ospedaliera Universitaria Dulbecco, Catanzaro; 4Center for Bleeding Disorders, Careggi University Hospital, Firenze; 5Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan; 6Regional Reference Center for the Treatment of Congenital Hemorrhagic Diseases, Parma University Hospital, Parma; 7Hematology, University Hospital Policlinico Umberto I, Roma; 8Inherited Bleeding Disorders Unit, IRCCS AOUBO, Bologna, Italy
625PDF: 0 -
PO86 | Emicizumab in patients with moderate hemophilia A and severe bleeding phenotype: single-center real-world experience A.L. Faccini, M. Biglietto, S. Sorella, E. Crisanti, M. Antonacci, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro, S. Ligia | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy
683PDF: 0 -
CO05 | Long-term management of upper extremity catheter-related thrombosis in female patients with cancer: a retrospective cohort study Chiara Cavallaro1,2, Paolo Santini1,2, Laura Leoni3, Carolina Mosoni1,2, Silvia D’Ambrosio1,2, Francesco Mancinetti1,2, Nicola Coletta1,2, Michela Iorio1,2, Angelo Porfidia1,2, Alessandro D’Errico1,2, Rosa Talerico1,2, Roberto Pola1,2 | 1Department of Aging, Orthopedic, and Rheumatologic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; 2Università Cattolica del Sacro Cuore, Rome; 3Vita-Salute University, San Raffaele Hospital IRCCS, Milan, Italy
607PDF: 0 -
PO45 | Routine prophylaxis with PD-FX concentrate in severe inherited FX deficiency: a case report S. Linari, L. Pieri, M. Attanasio, F. Salvianti, M. Coppo, E. Grisanti, F. Demartis, R. Fjerza, G. Castaman | Centre for Bleeding Disorders and Coagulation, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
548PDF: 0 -
PO44 | Emicizumab in acquired haemophilia A M. Leotta, A. Strangio, A. Ierardi, S. Prejanò, R C. Santoro | Hemostasis and Thrombosis Unit, Department Hemato-Oncology, Azienda Ospedaliero-Universitaria Renato; Dulbecco, Catanzaro, Italy
559PDF: 0 -
PO96 | Patient management with arteriovenous thrombotic manifestation and hemorrhagic complications M. Aversano, E. Cimino, L. Jr Valletta, C. Caputo, M. Romeo, M.D. Di Minno, A. Tufano, I.L. Calcaterra, C. De Luca, R. Russo, G. D’errico, P. Conca | Università degli Studi Federico II, Napoli, Italy
542PDF: 0 -
CO36 | Inhibitor titer at diagnosis and clinical course in acquired hemophilia A: a single-center experience C. Simion, B. Stocco, E. Dalla Porta, E. Campello, G. Furlan, L. Spiezia, G. Saggiorato, F. Sartorello, E. Zanon, P. Simioni | Department of Medicine – DIMED, University of Padua, Italy
509PDF: 0 -
PO26 | OUTCOMES OF DIRECT ORAL ANTICOAGULANTS IN UNUSUAL-SITE THROMBOSIS: IMPACT OF ACTIVE CANCER S. Guglielmo1, M. Lovisotto1, L. Scarano1, E. De Bon2, S. Barbar2 | 1Internal Medicine, Department of Medicine, Azienda Ulss 6 Euganea, Cittadella (PD), Italy; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda Ulss 6 Euganea, Cittadella (PD), Italy
288PDF: 91 -
PO50 | SUB-ANALYSIS OF INTERIM RESULTS FROM A PHASE 2 STUDY INVESTIGATING REGN9933A2 AND REGN7508CAT FOR THE PREVENTION OF CONTACT-MEDIATED VENOUS THROMBOEMBOLISM IN PATIENTS WITH ACTIVE CANCER UNDERGOING PERIPHERALLY INSERTED CENTRAL CATHETER PLACEMENT (ROXI-CATH) J. Zwicker1,2, A.P. Kithcart3, J. Kaplan3, Y-C. Cheng3, J.G. Raya3, J. Xiao3, S. Li3, K. Musgrave4, D.E. Gutstein3, G. Piazza5 | 1Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Weill Cornell Medical Center, New York, NY, USA; 3Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; 4Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; 5Brigham and Women’s Hospital, Boston, MA, USA
288PDF: 105 -
CO21 | Viscoelastic testing in inherited bleeding disorders: a cross-sectional comparison between viscoelastic coagulation monitoring and rotational thromboelastometry C. Simion, C. Samà, C. Bulato, G. Gottardi, D. Regazzo, E. Campello, P. Simioni | Department of Medicine – DIMED, University of Padua, Italy
566PDF: 0 -
-
PO08 | Efficacy and safety of thromboprophylaxis in hospitalized hematological patients: a monocenter retrospective study S. Cordella1,2, V. Coluccio3, M. Luppi1, M. Marietta1 | 1Department of Medical and Surgical Sciences, Section of Hematology. University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena; 2Clinical and Experimental Medicine PhD Programme, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena; 3Department of Hematology, Unità Sanitaria Locale di Modena, Italy
511PDF: 0 -
PO28 | CLINICAL IMPLICATIONS OF ANTICOAGULANT DRUG INTERACTIONS WITH TARGETED AND IMMUNE THERAPIES IN ONCOLOGY: A CONTEMPORARY RISK STRATIFICATION FRAMEWORK D. Dhami1, C. Solowiej Singh 1, M. Dhami 2 | 1Abrazo Internal Medicine Residency; 2Eastern Connecticut Hematology Oncology, Norwich, CT, USA
298PDF: 74 -
PO37 | CLINICAL SIGNIFICANCE OF SYMPTOMATIC AND INCIDENTAL VENOUS THROMBOEMBOLISM IN CANCER PATIENTS TREATED WITH APIXABAN P. Hussaini1, T.L. Larsen2, W. Ghanima1|3, A.E.A. Dahm1|2 | 1Institute of Clinical Medicine, University of Oslo, Oslo, Norway; 2Department of Hematology, Akershus University Hospital; Lørenskog, Norway; 3Clinic of Internal Medicine, Østfold Hospital, Grålum, Norway
243PDF: 86 -
PO66 | Viscoelastic tests in disseminated intravascular coagulation associated with aortic aneurysm A. M. Pizzini1, C. Biasoli2, M. Bovara3, E. Gesuete1, A. Fusco1, C. Fantoni1, P. Pedrazzi2, R. Mancini3, M. Silingardi1 | 1Ambulatorio Emostasi & Trombosi, Dipartimento Medico, Ospedale Maggiore AUSL Bologna; 2SSI Presa in Carico delle Malattie Emorragiche e Tromboemboliche della Romagna; 3Laboratorio Unico Metropolitano AUSL Bologna, Italy
575PDF: 0 -
CO07 | Real word management of anticoagulant therapy in brain metastasis: moving toward a multidisciplinary approach in complex cases E. Lotti1, C. Manneschi2, S. Fancelli2, F. Scolari1, F. Crudele1, D. Poli1, M. Berteotti1, D. Rossini3, S. Pillozzi2, L. Antonuzzo2,3, R. Marcucci1,3 | 1Disease Unit, Careggi University Hospital, Firenze; 2Oncology Unit, Careggi University Hospital, Firenze; <sup>3</sup>Department of Experimental and Clinical Biomedical Sciences, University of Firenze, Italy
569PDF: 0 -
Diagnosis and management of abnormal uterine bleeding in adolescence An expert Consensus Statement of SIGO (Italian Society of Gynecology and Obstetrics) and SISET (Italian Society for the Study of Hemostasis and Thrombosis)
2680PDF: 669 -
PO65 | Utilization of emicizumab in acquired hemophilia A: a case report C. Caputo, P. Conca, I.L. Calcaterra, E. Cimino, M. Romeo, M. Aversano, E. Franco, C. De Luca, G. D’errico, L. Jr Valletta, M. Di Minno, A. Tufano | Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
551PDF: 0 -
PO25 | EVOLUTION OF ANTICOAGULANT STRATEGIES AND CLINICAL OUTCOMES IN CANCER-ASSOCIATED THROMBOSIS: A LONGITUDINAL ANALYSIS OF THE START2 REGISTRY ONCO-VTE M. Marchetti1|2, T. Zollner1|2, OC. Cretu1|2, A. Chistolini3, R. Pancani4, L. Puccetti5, P. Sivera6, W. Ageno7, G. Elmi8, V. Fregoni9, V. Tonelli10, E. Antonucci11, D. Poli11|12, A. Falanga1|2, L. Barcella1|2 | 1Hemostasis & Thrombosis Center, Department of Transfusion Medicine, Papa Giovanni XXIII Hospital, Bergamo Italy; 2ERN EuroBloodNet; 3Hematology Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; 4Pulmonary Unit, Hospital of Siena, University of Siena, Siena, Italy; 5Hemostasis and Thrombosis Unit, Hospital of Siena, University of Siena, Siena, Italy; 6Haematology Unit, Ordine Mauriziano Hospital, Turin, Italy; 7Department of Medicine, University of Padua, Padua, Italy; 8Department of Medicine, Maggiore Hospital, Bologna, Italy; 9Department of Medicine, Sondalo Hospital, Sondalo, Italy; 10Angiology Unit, Sant'Eugenio Hospital, Rome, Italy; 11Arianna Anticoagulazione Foundation, Bologna, Italy; 12Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
277PDF: 63 -
PO50 | Treatment with BTK inhibitors in patients affected by chronic lymphocytic leukemia: safety and hemostasis L. Gurgoglione, C.A. Piro, I. Scortechini, I. Battilà, M.C. Merlo, A. R. Scortechini, S. Rupoli, A. Poloni | Hematology Unit, AOU delle Marche-Università Politecnica delle Marche, Italy
466PDF: 0 -
PO92 | Challenging management of portal vein thrombosis in a cirrhotic patient on hormone therapy after breast cancer L. Jr Valletta, C. De Luca, M. Aversano, C. Caputo, E. Cimino, P. Conca, A. Tufano, M.D. Di Minno | AOU Federico II Napoli, Italy
518PDF: 0 -
PO47 | Hemophilia A and antithrombin deficiency: a case of natural hemostatic rebalancing L. Torrieri, S. Ligia, E. Baldacci, R. Mormile, S. Sorella, R. Ciciani, M. Biglietto, N. Zhdanovskaya, A. Delli Paoli, A. Tirnetta, M. Lorenzon, C. Santoro | Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Roma, Italy
565PDF: 0 -
PO64 | MANAGEMENT OF BLEEDING RISK IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SYSTEMIC THERAPY: A SURVEY OF CLINICAL PRACTICE T. Van Broeckhoven1|9, E. Van Gansewinkel5|10, J. De Bruijne2, F. Eskens3, D. De Groot4, K. Hermans5, N. Mohammad6, F. Van Vilsteren7, C. Verslype8, W. Moris9, M. Roest10, B. De Laat10 , J. De Vos-Geelen5, M. Kramer1|9 | 1Department of Gastroenterology and Hepatology, GROW – Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; 2Department of Gastroenterology & Hepatology, Utrecht University, University Medical Center Utrecht, The Netherlands; 3Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, the Netherlands; 4Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, the Netherlands; 5Department of Internal Medicine, Division of Medical Oncology, GROW – Research Institute for Oncology & Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; 6Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands; 7Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands; 8Digestive Oncology, University Hospitals Leuven, Belgium; 9Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands; 10Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Netherlands, on behalf of the Dutch Hepatocellular & Cholangiocarcinoma Group
259PDF: 77 -
PO81 | Direct oral anticoagulants in atypical site vein thrombosis: a single centre experience focused on cancer patients U. Mazzarelli1, A. Guida1, L. Agrelli1, M. Amato1, R. Guarrasi2, L. Santaniello2, C. Cardamone1, P. Vitale1, M. Triggiani1 | 1Centro per le Malattie Emorragiche Congenite e Malattie Trombotiche UOC Clinica Immunologica e Reumatologica AOU S. Giovanni di Dio e Ruggi d’Aragona, Salerno; 2UOC Clinica Oncologica AOU S. Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy
589PDF: 0 -
PO37 | Single centre experience on anticoagulation in carriers of non-mild inherited thrombophilia: direct oral anticoagulants (DOAC) efficacy and safety M. D’uva1,2, G. La Barba1, G. Montanaro1, M. Di Ianni1,2, P. Ranalli1,2 | 1Hematology Unit, S. Spirito Hospital, Pescara; 2Department of Medicine and Aging Sciences, D’Annunzio University, Chieti, Italy
592PDF: 0 -
PO30 | LONG-TERM ANTICOAGULANT THERAPY AND PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM IN ADVANCED OVARIAN CANCER V. Bitsadze 1, A. Vorobev 1, J. Khizroeva 1, A. Solopova 1, M. Tretyakova 1, N. Gashimova 1, K. Grigoreva 1, A. Khisamieva 1, J. Gris 1|2, I. Elalamy1|3|4, G. Gerotziafas1|3|4, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 2Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 3Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 4Hospital Tenon, Paris, France
270PDF: 73 -
PO42 | Acquired Von Willebrad syndrome in patients with myeloproliferative syndrome: literature review and single-center experience A. Strangio, M. Leotta, A. Ierardi, R C. Santoro | UO Emofilia, Emostasi e Trombosi, AOU R Dulbecco, Catanzaro, Italy
482PDF: 0 -
CO38 | Management of pregnancy, delivery, and postpartum in Italian carriers and women with hemophilia A and B S. Linari1, B. Pollio2, A. Ferretti3, M. Napolitano4, E. Grandone5, S. Siboni6, Ab. Aru7, E. Bertoni8, C. Biasoli9, I. Cantori10, P. Di Gregorio11, G. Lassandro12, G. Sottilotta13, A. Strangio14, Mr. Villa15, A. Rocino16, G. Castaman1 | 1Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Firenze; 2Regional Reference Center for Inherited Bleeding and Thrombotic Disorders, Transfusion Medicine, Regina Margherita Children Hospital, Turin; 3Center for Hemorrhagic and Thrombotic Diseases, IRCCS A. Gemelli University Hospital Foundation, Roma; 4Department of Health Promotion, Maternal-Childhood, Internal Medicine of Excellence G. D’Alessandro, University of Palermo; 5Thrombosis and Hemostasis Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo; 6Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan; 7Pediatric Onco-Hematology Center, Microcitemico Hospital Cagliari; 8Pediatric Oncohematology and Bone Marrow Transplant “BMT” Unit, Children’s Hospital, Spedali Civili, Brescia; 9Hemophilia and Transfusion Center, Bufalini Hospital, Cesena; 10Hemophilia Center, Department of Transfusion Medicine, Hospital of Macerata; 11Transfusion Medicine Department, SS. Annunziata Hospital, Chieti; 12B. Trambusti General and Specialised Pediatrics Unit, Giovanni XXIII Hospital, University of Bari; 13Hemophilia Center, Grande Ospedale Metropolitano, Reggio Calabria; 14Center for Hemorrhagic and Thrombotic Disorders, Pugliese Ciaccio Hospital, Catanzaro; 15Hemophilia and Thrombosis Center, Haematology Unit, Ospedale del Mare Hospital, Naples; 16Past President of the Italian Association of Hemophilia Centers, Italy
529PDF: 0 -
PO53 | PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF REGN7508CAT FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I) J. Zwicker1, M. P. O’Brien2, M. Carrier3, J. Connors4, A. Falanga5, A. Manzano6, R. Mcbane7, Y.Y. Janjigian1, G. O’Kane8, M. Onisko2, J. Kaplan2, A.P. Kithcart2, D.E. Gutstein2, A. Khorana9, M. F. Walsh2 | 1Memorial Sloan Kettering Cancer Center, New York, USA; 2Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; 3University of Ottawa, Ottawa, ON, Canada; 4Harvard Medical School, Boston, MA, USA; 5Hospital Papa Giovanni XXIII, Bergamo, Italy; 6Hospital Universitario 12 de Octubre, Madrid, Spain; 7Mayo Clinic, Rochester, MN, USA; 8St. Vincent's University Hospital and School of Medicine, University College Dublin, Dublin, Ireland; 9James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
283PDF: 90 -
PO36 | EXTENDED DURATION REDUCED DOSE ANTICOAGULATION IN CANCER-ASSOCIATED THROMBOSIS: A REAL-WORLD COHORT WITH LONG TERM FOLLOW UP A. Bhide1, I. Welding1, O. Ogunbiyi1, S. Hawkins2, E. Greenlay1, N. Prasannan1, J. Westwood1, M. Thomas1 | 1Department of Clinical Haematology, University College London Hospital, London; 2Data Clinic, University College London, UK; A. Bhide and I. Welding joint First Authors
283PDF: 89 -
PO31 | Comparative analysis of anticoagulant therapy in patients over 90 years old: vitamin K antagonists versus direct oral anticoagulants G. Sottilotta1, P. Arrigo2, S. Cuzzocrea1, D. Megalizzi1, F. Luise3 | 1UOSD Microcitemie, Emostasi e Trombosi, Grande Ospedale Metropolitano di Reggio Calabria; 2Associazione Italiana Pazienti Anticoagulati, Sezione di Reggio Calabria; 3Laboratorio Analisi. Grande Ospedale Metropolitano di Reggio Calabria, Italy
531PDF: 0 -
PO74 | Combined therapeutic approaches in a patient with hereditary hemorrhagic telangiectasia (HHT) and cardiovascular comorbidities M. Romeo, E. Cimino, P. Conca, I.L. Calcaterra, G. Iannuzzo, C. Caputo, M. Aversano, E. Franc, S. Donnarumma, C. De Luca, M.N.D. Di Minno, A. Tufano | Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
683PDF: 0 -
PO38 | Rates of hemorrhagic events and hemodialysis circuit thrombosis in patients with end-stage renal disease on hemodialytic treatment receiving a factor-XI inhibitor: a systematic review and meta-analysis D. Santagata, G. Barbui, M.P. Donadini, A. Squizzato | Department of Medicine and Surgery, Research Center on Thromboembolic Disorders and Antithrombotic Therapies, University of Insubria, Varese and Como, Italy
542PDF: 0 -
CO33 | Acquired hemophilia A in Liguria, Italy: what six years of data reveal C. Vernarecci1, A. C. Molinari1, P. Ballarino2, M. Caiti2, E. Cenni2, P. Moscatelli2, L. Banov1 | 1IRCCS Istituto Giannina Gaslini, Genova; 2IRCCS Policlinico San Martino, Genova, Italy
549PDF: 0 -
PO27 | B-cell lymphoproliferative disorder and acquired coagulopathy: an insidious link C. Caputo, P. Conca, I.L. Calcaterra, E. Cimino, M. Romeo, M. Aversano, E. Franco, C. De Luca, R. Russo, C. Fierarossa, M.N.D. Di Minno, A. Tufano | Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
552PDF: 0 -
PO43 | Extended treatment with reduced dose of direct oral anticoagulants in patients with venous thromboembolism: a retrospective study A. Pannunzio1, E. Valeriani1, I.M. Palumbo1, D. Menichelli1, T. Brogi2, S. Marucci2, D. Pastori2, P. Pignatelli2 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Roma, Italy
585PDF: 0 -
PO13 | Monitoring of anti-factor XA activity levels in patients treated with direct oral anticoagulants and concomitant tyrosine kinase inhibitors agents: a monocentric experience E. Santacroce1,2, C. Santoro1, E. Baldacci1, S. Ligia1, R. Mormile1, M. Biglietto1, M. Totaro1, F. R. Mauro1, M. Breccia1, A. Chistolini1 | 1Department of Translational and Precision Medicine, Haematology, Sapienza University of Roma; 2Department of Clinical and Molecular Medicine, Sapienza University of Roma, Italy
574PDF: 0 -
CO39 | Artificial intelligence in hemophilia management: challenging the need for experts G. Sottilotta1, D. Megalizzi1, F. Luise2 | 1UOSD Microcitemie - Emostasi e Trombosi. Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria; 2Laboratorio Analisi, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria, Italy
546PDF: 0 -
CO04 | Direct oral anticoagulants in antiphospholipid syndrome: a single center real-life experience A. Hoxha1, E. Campello1, F. Ahmad2, L. Spiezia1, P. Scarinzi1, G. Gobbo1, S. Gavasso1, F. Sartorello1, C. Simion1, E. Zanon1, P. Simioni1 | 1Internal Medicine Unit, Thrombotic and Haemorrhagic Centre, Department of Medicine - DIMED; 2Department of Statistical Sciences) University of Padova, Italy
700PDF: 0 -
-
OC04 | DIRECT ORAL ANTICOAGULANTS PROVIDE EFFECTIVE THROMBOPROPHYLAXIS IN NEWLY DIAGNOSED MYELOMA: REAL WORLD FINDINGS FROM THE ATOMM STUDY T. Bull1, Heamstar Collaborators2, W. Wilson3, E. Ganendra4, M. Thomas5, R. Alikhan6, M. Karanth1, M. Camilleri7 | 1West Suffolk Hospital NHS Foundation Trust, UK; 2Haematology Specialty Training Audit and Research HaemSTAR Network, UK; 3University College London Clinical Trial Centre, UK; 4North West Anglia NHS Foundation Trust, UK; 5University College London Hospitals, UK; 6Cardiff and Vale University Health Board, Wales, UK; 7Cambridge University Hospitals NHS Foundation Trust, UK
384PDF: 87 -
Bleeding complications of oral anticoagulant therapy: from ISCOAT to the START Register A memory of Gualtiero Palareti
1029PDF: 187 -
PO61 | ACTN1-related thrombocytopenia and severe hyperhomocysteinemia: a case report A. Pozzi, G. Rosati, M. Padrini, S. Laurenti, G. Ferrari, R.M. Medici, C. Barale, I. Russo, A. Morotti | University of Turin, San Luigi Hospital, Orbassano (TO), Italy
508PDF: 0 -
PO18 | THE THROMBO-INFLAMMATION AXIS AS PREDICTOR OF TOXICITY IN PATIENTS TREATED WITH CAR-T CELLS C. Fernández-Arias1, M. Marcos-Jubilar1, M. Panizo1, C. Vázquez-Puerta2, J.R. González-Porras2, M. Ibáñez1, A. Queralt1, M. Carrasco1, M.B. Villacrés1, C. Conde1, P. Elizalde1, S. Huerga1, A. Alfonso1, P. Rodríguez-Otero1, S. Villar1, M.A. Canales1, J. Rifón1, F. Prósper1, J.A. Páramo1, J. Orbe1, R. Lecumberri1 | 1Clínica Universidad de Navarra, Pamplona; 2Hospital Clínico Universitario de Salamanca, Salamanca, Spain
319PDF: 64 -
Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey
1385PDF: 269HTML: 175Supplementary: 84 -
PO82 | Retrospective application of the TH2 score in a multicenter cohort of ITP patients: a reliable predictive tool or a score in need of refinement? C. Giubbilei1, M. Defina2, S. Rosati3, M. Rocco3, A. Votto4, F. Simonetti5, F. Paoletti6, V. Carrai1 | 1Hematology Unit, AOU Careggi; 2Hematology unit AOU Senese; 3Hematology Unit Azienda Sanitaria Toscana Centro; 4Hematology Unit, AOU Pisana; 5Hematology Unit, Ospedale Versilia; 6Hematology Unit, Azienda Sanitaria Nord Ovest, Italy
513PDF: 0 -
PO32 | ANTICOAGULANT THROMBOPROPHYLAXIS IN AGGRESSIVE LYMPHOMAS PATIENTS: PREDICTIVE THROMBOTIC RISK SCORES AND RISK FACTORS L. Gurgoglione1, G. Gini1, S. Rupoli1, A. Poloni1|2 | 1Hematology, AOU delle Marche, Ancona; 2Università Politecnica delle Marche, Ancona, Italy
314PDF: 70 -
PO12 | Characterisation and real word clinical data of HEM006, a newly formulated intranasal spray desmopressin (DDAVP) to address a global treatment gap G. De Giorgi1, A. Gringeri2, R. Franceschini1, A. Koganti3 | 1Hemorare Srl, Italy; 2Fondazione Charta, Milan, Italy; 3Quenya LLC, USA
517PDF: 0 -
PO70 | Clinical safety and monitoring of apixaban combined with tacrolimus and everolimus in kidney transplant patients: a prospective study S. Guglielmo1, E. De Bon2, L. Scarano1, R. Fabris1, E. Pierobon3, S. Barbar2 | 1Internal Medicine, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; 3Nephrology and Dialysis Unit, Azienda ULSS 6 Euganea, Cittadella and Camposampiero, Padova, Italy
564PDF: 0 -
CO40 | The co-inheritance of two ITGB3 variants exerting additive detrimental effects on platelets leads to variant Glanzmann thrombasthenia N. Arndt1, E. Falcinelli1, A. Zamora-Cánovas2, A. Sánchez Fuentes2, A. Marín-Quilez2, I. Tano1, M.D.M. Nieto-Hernández3, J.M. Bastida4, J. Rivera2, P. Gresele1, L. Bury1 | 1Department of Medicine and Surgery, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy; 2Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Pascual Parrilla, ISCIII-CIBERER, Murcia, Spain; 3Servicio de Hematología, Hospital Universitario de Jaen, Spain; 4Departamento de Hematología, Complejo Asistencial Universitario de Salamanca “CAUSA”, Instituto de Investigación Biomédica de Salamanca “IBSAL”, Centro de Investigación del Cáncer, IBMCC-CSIC, Universidad de Salamanca “USAL”, Salamanca, Spain
546PDF: 0 -
PO91 | Disseminated intravascular coagulation with deep vein thrombosis in a frail patient: an extreme manifestation triggered by sepsis during SGLT2i therapy M. Vacca1, M.V. Cherchi1, S. Che1, G.A.M.L. Costanzo2, D. Firinu2, M. Mantega1, S. Del Giacco2 | 1Ospedale Sirai, ASL Sulcis, 2Università degli Studi di Cagliari, Italy
719PDF: 0 -
CO32 | Major surgery in patients with severe hemophilia A without inhibitors receiving prophylaxis with fitusiran E. Zanon, C. Simion, A. Napolitano, L. Spiezia, P. Simioni | Haemophilia Center, First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
496PDF: 0 -
PO40 | RADAR, UK-MRA MYELOMA XV - COMPARING MRD-GUIDED TREATMENT ESCALATION AND DE-ESCALATION STRATEGIES IN PATIENTS WITH NEWLY DIAGNOSED MYELOMA SUITABLE FOR STEM CELL TRANSPLANTATION: THROMBOPROPHYLAXIS SUBGROUP STUDY PROTOCOL Z. Sayar, on behalf of the RADAR Investigators | Whittington Health NHS Trust and Royal Free Hospital, London, UK
282PDF: 86 -
CS02 | Functional and structural impairments of the cerebral microcirculation in a mouse model of hemophilia A G. Venturin1, C. Olgasi2, C. Borsotti1, P.E. Di Simone1, E. Spicuglia1 A. Cucci1, C. Sgromo1, A. Follenzi2,3 | 1Department of Health Science, Università del Piemonte Orientale, Novara; 2Department of Translational Medicine, Università del Piemonte Orientale, Novara; 3Department of Attività Integrate Ricerca Innovazione, Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy
674PDF: 0 -
PO61 | RISK FACTORS FOR INTRACRANIAL HEMORRHAGE: AN UMBRELLA REVIEW TO INFORM MACHINE LEARNING PREDICTION MODELS IN GLIOMA PATIENTS RECEIVING ANTICOAGULATION T.A. Adeyemo, S. Greenley, F. Ware, W. Jones, A. Maraveyas, F. Haque | 1Centre of Excellence for Data Science, Artificial Intelligence and Modelling DAIM, Faculty of Science and Engineering, University of Hull, UK; 2Hull York Medical School, Hull, UK; 3Academic Library Services, University of Hull, UK; 4NHS Humber Health Partnership, Hull, UK
343PDF: 93
